Autonomix Medical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
29.0%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$22.68next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| U.S. IDE Clinical Trial Commencement | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Accumulated Deficit Quarterly-67.1MTarget: Reduce deficit through commercialization
Operating Cash Flow Quarterly-12.3MTarget: Achieve positive operating cash flow
Working Capital Quarterly5.9MTarget: Maintain sufficient liquidity for clinical trials
Watch Items
- Going Concern Risk and Cash RunwayTrigger: Cash resources falling below levels required to fund operations beyond Q4 2026Action: Secure additional equity or debt financing (estimated $30–$36 million needed to reach first commercialization)
- FDA IDE Submission and Clinical Trial InitiationTrigger: Delay in FDA approval of Investigational Device Exemption (IDE) for U.S. clinical trials planned for late 2026Action: Engage with regulatory consultants and address FDA feedback on the Sensing and RF Ablation System
- Nasdaq Listing ComplianceTrigger: Failure to maintain minimum bid price or other continued listing requirementsAction: Execute the approved 1-for-21 reverse stock split effective June 24, 2026, to restore compliance
Research as of 20 Jun 2026